Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS

Amyotrophic Lateral Sclerosis Clinical Trial

— MITOTARGET  

Official title:

Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00868166
• Other study ID #: WN29853
• Secondary ID: EudraCT Number:2
• Status: Completed
• Phase: Phase 3
• Start date: April 30, 2009
• Est. completion date: September 30, 2011

Study information

• Verified date: February 2020
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as compared to placebo, assessed by the 18-month survival rate.

Description:

A stand alone treatment with TRO19622 is not acceptable for ethical reasons. Riluzole is an approved and widely used ALS treatment in the European community, in Japan and in the USA.

Therefore, in this study, TRO19622 will be assessed as add-on to riluzole in patients suffering from ALS.

At the start of the study, patients will be randomized to one of two groups : TRO19622 (330 mg QD or placebo (once a day).

Each treatment will be administered for 18 months under double-blind conditions. The product under evaluation will be administered to patients receiving the standard of care for ALS, including riluzole.

Riluzole dosage (50 mg bid) must be stable and well tolerated for at least one month prior to inclusion into the study.

After the double-blind period, open-label administration of TRO19622 will be allowed for safety and survival assessments and until efficacy results are available.

A separate open-label protocol will be written 6 months after the randomization of the last patient into the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 512
• Est. completion date: September 30, 2011
• Est. primary completion date: September 30, 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with sporadic or familial Amyotrophic Lateral Sclerosis

• Patients with a clinical diagnosis of laboratory-supported probable, probable, or definite ALS according to the modified El Escorial criteria8.

• Have signed an Informed Consent to participate to the trial before any study related procedure has taken place.

• Be of age >18 (exclusive) and < 80 years (inclusive).

• If a female, not lactating, has a negative pregnancy test and agrees to use an effective method of birth control.

• Onset of ALS Symptoms (weakness) for more than 6 months (inclusive) and less than 36 months(inclusive).

• Slow vital capacity (SVC), measured three times, one of the measure being >/= 70% of that predicted.

• Treated with riluzole at the stable dose of 50 mg bid for at least 30 days before enrolment.

Exclusion Criteria:

• Tracheostomy, invasive ventilation, or non invasive positive pressure ventilation (NIPPV).

• Gastrostomy.

• Evidence of major psychiatric disorder or clinically evident dementia.

• Diagnosis of a neurodegenerative disease in addition to ALS.

• Have a current medication that could interfere with TRO19622 pharmacokinetics:

tamoxifene.

• Have current medications that could interfere with TRO19622 absorption such as ezetimibe, bile salts chelators (cholesteramine), fibrates, phytosterols, niacin (vitamin B3),fish oils. Have a current medication of lipid lowering agents other than statins.

• Known hypersensitivity to any component of the study drug.

• Patients with known intolerance or contra-indication to riluzole.

• Have a recent history (within the previous 6 months) or current evidence of alcohol or drug abuse.

• Have concurrent unstable disease involving any system eg, carcinoma other than basal cell carcinoma, any cardiac dysrhythmia, myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac insufficiency, angina symptoms, current symptoms of Coronary Artery Disease, or any other condition that in the opinion of the Investigator would make the patient unsuitable for study participation.

. In Germany: Have any cardiac dysrhythmia, myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac insufficiency, angina symptoms, current symptoms of Coronary Artery Disease or any cardiovascular illness known or identified at the screening or inclusion visits, or have concurrent unstable disease involving any system eg, carcinoma other than basal cell carcinoma or any other condition that in the opinion of the Investigator would make the patient unsuitable for study participation.

• Having a baseline QTc (Bazett) > 450 msec for males and > 470 msec for females.

• Patients with known hepatitis B/C or HIV positive serology.

• Be pregnant female or lactating.

• Have renal impairment defined as blood creatinine > 1:5 X upper limit of normal.

• Have hepatic impairment and/or liver enzymes (ALAT or ASAT) > 3 X ULN.

• Hemostasis disorders or current treatment with oral anticoagulants.

• Be possibly dependent on the Investigator or the Sponsor (eg, including, but not limited to, affiliated employee).

• Participated in any other investigational drug or therapy study with a non approved medication, within the previous 3 months.

• Patients without Social Security Insurance (France).

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Drug:
• Olesoxime
2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
• Placebo Comparator
2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
• Riluzole
Riluzole given as add-on therapy 50mg bid

Locations

Country	Name	City	State
Belgium	University Hospital Gasthuisberg - Dept Neurology - Herestraat 49	Leuven
France	HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel	Bron Cedex
France	CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement	Lille
France	Centre SLA Limoges - Service de Neurologie	Limoges
France	Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires	Marseille
France	Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac	Montpellier
France	CHU de Nice - Hôpital de l'Archet 1 - Centre de Référence pour les Maladies Neuromusculaires et la SLA	Nice
France	Groupe Hospitalier PITIE-SALPETRIERE - Fédération des Maladies du Système Nerveux	Paris
Germany	Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz für ALS und andere Motoeneuronenerkrankungen	Berlin
Germany	Universitätsklinik und Poliklinik für Neurologie - Martin-Luther-Universität Halle-Wittenberg	Halle
Germany	Neurologische Klinik Medizinische Hochschule	Hannover
Germany	Universitäts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik	Ulm
Spain	Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10	Madrid
United Kingdom	King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry	London
United Kingdom	Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences	Sheffield

Sponsors (2)

Lead Sponsor	Collaborator
Hoffmann-La Roche	European Commission

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival Rate at 18 Months	Overall survival was defined from the date of randomization until the date of death (event) or last known alive date (censored). If the death date was after 18 months, the participant was censored at 18 months (548 days). Participants still alive at or after 18 months were censored at 18 months/ 548 days. All data over the 18-month follow-up period after randomization, and participant survival status at the 18-month follow-up visit for participants who withdrew prematurely from the study for reasons other than death were included.	From the date of randomization until the date of death or last follow-up censored at 18 months (548 days)
Secondary	Percentage of Participants With Failure Over 18 Months	Time to failure was defined as the time from randomization to the time of the first event to consider (Tracheostomy, invasive ventilation [IV] or non invasive ventilation [NIV])	From randomization to the time of the first event to consider at 18 months (548 days)
Secondary	Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)	The ALSFRS-R is an ordinal rating scale (0 through 4) used to determine the ALS participant's self assessment of their ability and need for assistance in 12 activities or functions. This is a validated scale, both in person and by phone, which provides a total score from four sub-scores which assess speech and swallowing, (bulbar function), use of upper extremities (cervical function), gait and turning in bed (lumbar function), and breathing (respiratory function). Total scores range from 0 (most impaired) to 48 (normal ability).	Inclusion, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 15 and Month 18
Secondary	Percentage of Participants With a Global ALS FRS-R Score of <30 or Death	Percentage of participants with a global ALS FRS-R score of < 30 or death was estimated using the Kaplan-Meier method in the ITT, with a two-tailed log-rank, both stratified by site of onset (bulbar or spinal) and non-stratified. The ALSFRS-R is an ordinal rating scale (0 through 4) used to determine the ALS participant's self assessment of their ability and need for assistance in 12 activities or functions. This is a validated scale, both in person and by phone, which provides a total score from four sub-scores which assess speech and swallowing, (bulbar function), use of upper extremities (cervical function), gait and turning in bed (lumbar function), and breathing (respiratory function). Total scores range from 0 (most impaired) to 48 (normal ability).	Month 18 (548 days)
Secondary	Slow Vital Capacity (SVC) Percent Predicted	SVC as a percent of the predicted value was evaluated and reported.	Baseline, Inclusion, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15 and Month 18
Secondary	Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months		Month 18 (548 days)
Secondary	Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups	MMT score involved the examination of 30 items. These 30 items are scored from 0 (no trace of contraction) to 5 (normal power at first try). The global score is the sum of the item scores and can range from 0 to 150. Higher score indicates some power.	Inclusion, Month 3, Month 6, Month 9, Month 12, Month 15 and Month 18
Secondary	The Single-Item Mc Gill Quality of Life Scale	The single-item McGill quality of life scale evaluated the following question "Considering all parts of my life - physical, emotional, social, spiritual, and financial - over the past two (2) days, the quality of my life has been…"as a score of 1 to 10 on a visual analog scale where 0 is very bad and 10 is excellent.	Inclusion, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15 and Month 18